Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Appetite

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    202 result(s) found for: Appetite. Displaying page 1 of 11.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002318-15 Sponsor Protocol Number: 010921 Start Date*: 2021-09-15
    Sponsor Name:Copenhagen University Hospital, Amager and Hvidovre, Department of Clinical Research
    Full Title: A pharmacological trial with Sativex® and gentamicin for optimized pharmacological treatment of older patients with a focus on appetite stimulation and renal risk drugs
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10061273 Malnutrition PT
    20.0 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    23.0 10027433 - Metabolism and nutrition disorders 10061428 Decreased appetite PT
    22.0 10028395 - Musculoskeletal and connective tissue disorders 10056720 Muscle mass PT
    21.0 10022891 - Investigations 10053349 Pharmacokinetic study LLT
    21.1 10022891 - Investigations 10018355 Glomerular filtration rate PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001055-50 Sponsor Protocol Number: EP-001 Start Date*: 2016-08-08
    Sponsor Name:Empros Pharma AB
    Full Title: A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and...
    Medical condition: Obesity and diabetes, type 2.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008377-56 Sponsor Protocol Number: 2008-249 Start Date*: 2009-03-10
    Sponsor Name:Palliativ medicinsk afdeling, Bispebjerg Hospital
    Full Title: Melatonin for træthed og andre symptomer hos patienter med fremskreden kræft
    Medical condition: Træthed og andre symptomer hos patienter med freskreden kræft i palliativ fase
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033372 Pain and discomfort NEC HLT
    9.1 10016258 Fatigue management LLT
    9.1 10022437 Insomnia LLT
    9.1 10003028 Appetite lost LLT
    9.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023648-34 Sponsor Protocol Number: HT-ANAM-301 Start Date*: 2011-09-15
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    14.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) DE (Completed) CZ (Completed) IT (Completed) SI (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023649-31 Sponsor Protocol Number: HT-ANAM-302 Start Date*: 2011-07-29
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy ...
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10002646 Anorexia LLT
    13.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003775-39 Sponsor Protocol Number: F1D-MC_X311 Start Date*: 2008-10-29
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis
    Medical condition: patients with amyotrophic lateral sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000464-27 Sponsor Protocol Number: ART27.13-100 Start Date*: 2020-10-29
    Sponsor Name:Artelo Biosciences Limited
    Full Title: A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss
    Medical condition: Cancer anorexia and weight loss
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10002646 Anorexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001670-34 Sponsor Protocol Number: AZP01-CLI-002 Start Date*: 2015-01-26
    Sponsor Name:Alize Pharma
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in...
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10003018 Appetite and general nutritional disorders HLGT
    17.1 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    17.1 10027433 - Metabolism and nutrition disorders 10003022 Appetite disorders HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001594-40 Sponsor Protocol Number: UNOLE0526 Start Date*: 2016-05-10
    Sponsor Name:University of Leicester
    Full Title: SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A randomised double-blind placebo-controlled trial (SEESAW)
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003083-30 Sponsor Protocol Number: PLAQHV Start Date*: 2019-01-31
    Sponsor Name:UZ Leuven
    Full Title: The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects
    Medical condition: The study is meant to have a better understanding in obesity and how we can prevent/cure it. Therefore, the product will first be tested in healthy, lean volunteers.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001625-96 Sponsor Protocol Number: PLAQOW Start Date*: 2019-01-31
    Sponsor Name:UZ Leuven
    Full Title: The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in overweight female subject
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005585-32 Sponsor Protocol Number: 111111733104 Start Date*: 2016-06-24
    Sponsor Name:Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen
    Full Title: Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004946-41 Sponsor Protocol Number: s57223 Start Date*: 2014-11-19
    Sponsor Name:KULeuven
    Full Title: The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers
    Medical condition: healthy volunteers no medical condition; drug will be studied because it is known to influence gastric motility
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005631-29 Sponsor Protocol Number: 24420221 Start Date*: 2008-06-18
    Sponsor Name:Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital
    Full Title: Cannabinoid CB1 receptor agonist treatment in severe chronic anorexia nervosa
    Medical condition: severe chronic Anorexia Nervosa
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002649 Anorexia nervosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-023650-36 Sponsor Protocol Number: HT-ANAM-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Helsinn Therapeutics (U.S.), Inc.
    Full Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): An Extension Study (ROMANA-3)
    Medical condition: Non-Small Cell Lung Cancer related Cachexia (NSCLC-C)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) NL (Completed) GB (Completed) ES (Completed) CZ (Completed) PL (Completed) DE (Completed) IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2009-017193-20 Sponsor Protocol Number: S51994 Start Date*: 2010-01-28
    Sponsor Name:UZLeuven
    Full Title: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.
    Medical condition: healthy volunteers none; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003016-87 Sponsor Protocol Number: C3651003 Start Date*: 2023-03-13
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF G...
    Medical condition: Cachexia, a loss of weight due to the catabolism of muscle and fat tissue. The progressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10064015 Cancer cachexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) HU (Completed) BG (Ongoing) ES (Ongoing) PL (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023179-25 Sponsor Protocol Number: Start Date*: 2011-09-13
    Sponsor Name:Aintree University Hospital NHS Foundation Trust [...]
    1. Aintree University Hospital NHS Foundation Trust
    2. UNIVERSITY OF LIVERPOOL
    Full Title: Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome
    Medical condition: Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002274-31 Sponsor Protocol Number: U1111-1215-8606 Start Date*: 2020-12-16
    Sponsor Name:Department of Biomedical Sciences, University of Copenhagen
    Full Title: Young adults with early-onset obesity treated with semaglutide
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10029885 Obesity, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004391-29 Sponsor Protocol Number: InBoTox Start Date*: 2016-04-06
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
    Full Title: Effectiveness of intragastric injection of botulinum toxin by endoscopy in obese patients in surgical waiting list. Study InBoTox
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 04:15:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA